Skip to content

Arcutis Biotherapeutics

US · ARQT #2465 by market cap Listed 2020
26.36 -0.81 -2.98%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Quant vs Street three independent views, side by side

StockVane factor grade
C
Momentum strategy signal
Sell
Analyst consensus
Buy

Signals diverge - worth digging into why.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 5 analysts

Buy
Avg price target 42.00 +59.3%
Price target rangecurrent 26.36
Low38.00
Avg42.00
High48.00
Buy 100% Hold 0% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-05 Morgan Stanley -- Buy 38.00
2026-11-05 H.C. Wainwright -- Buy 40.00
2026-11-04 TD Cowen -- Buy 40.00
2026-10-19 Guggenheim -- Buy 44.00
2026-10-15 Cantor Fitzgerald -- Buy 48.00
2026-08-10 H.C. Wainwright -- Buy 34.00
2026-08-06 Morgan Stanley -- Buy 38.00
2026-08-06 Needham -- Buy 40.00
2026-08-06 H.C. Wainwright -- Buy 34.00
2026-08-05 TD Cowen -- Buy 35.00
2026-08-05 Guggenheim -- Buy 38.00
2026-07-16 Guggenheim -- Buy 35.00
2026-06-30 Needham -- Buy 36.00
2026-05-11 H.C. Wainwright -- Buy 34.00
2026-05-07 TD Cowen -- Buy 35.00
2026-05-07 Morgan Stanley -- Buy 34.00
2026-05-07 Needham -- Buy 36.00
2026-05-07 H.C. Wainwright -- Buy 34.00
2026-04-23 TD Cowen -- Buy 35.00
2026-04-22 Morgan Stanley -- Buy 35.00
2026-04-15 Needham -- Buy 36.00
2026-03-02 H.C. Wainwright -- Buy 34.00
2026-02-27 Goldman Sachs -- Hold 33.00
2026-02-26 TD Cowen -- Buy 35.00
2026-02-26 Morgan Stanley -- Buy 35.00

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-04 After close ±12.67% -20.70% (beat)
2026/Q2 2026-08-05 After close ±12.50% -2.47% (in line)
2026/Q1 2026-05-06 After close ±9.68% -14.52% (beat)
2025/Q4 2026-02-25 After close ±13.18% +5.78% (in line)
2025/Q3 2025-10-28 -- ±15.85% +27.04% (beat)
2025/Q2 2025-08-06 After close ±14.21% -8.07% (in line)
2025/Q1 2025-05-06 After close ±18.89% -4.33% (in line)
2024/Q4 2025-02-25 After close ±25.48% +8.36% (in line)
2024/Q3 2024-11-06 After close ±20.13% +7.66% (in line)
2024/Q2 2024-08-14 After close ±17.75% -11.27% (in line)
2024/Q1 2024-05-14 After close ±33.32% +13.65% (in line)
2023/Q4 2024-02-27 -- ±31.15% +9.70% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Arcutis Biotherapeutics discussion 0 comments

Add a comment